DeepClassPathway: Molecular pathway aware classification using explainable deep learning.

Journal: European journal of cancer (Oxford, England : 1990)
Published Date: Sep 30, 2022

Abstract

OBJECTIVE: HPV-associated head and neck cancer is correlated with favorable prognosis; however, its underlying biology is not fully understood. We propose an explainable convolutional neural network (CNN) classifier, DeepClassPathway, that predicts HPV-status and allows patient-specific identification of molecular pathways driving classifier decisions.

Authors

  • Elia Lombardo
    Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany.
  • Julia Hess
    Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.
  • Christopher Kurz
    Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München (LMU Munich), Garching bei München, 85748, Germany.
  • Marco Riboldi
    Department of Medical Physics, Ludwig-Maximilians-Universität München, Germany.
  • Sebastian Marschner
    Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany.
  • Philipp Baumeister
    Klinik für Urologie, Luzerner Kantonsspital, Luzern, Switzerland.
  • Kirsten Lauber
    Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.
  • Ulrike Pflugradt
    Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.
  • Axel Walch
    Research Unit Analytical Pathology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
  • Martin Canis
    Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, LMU Munich, Munich, 81377, Germany.
  • Frederick Klauschen
    Pathologisches Institut, Ludwig-Maximilians-Universität München, Thalkirchner Str. 36, 80337, München, Deutschland. f.klauschen@lmu.de.
  • Horst Zitzelsberger
    Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.
  • Claus Belka
    Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
  • Guillaume Landry
    Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München (LMU Munich), Garching bei München, 85748, Germany.
  • Kristian Unger
    Department of Radiation Oncology, University Hospital, LMU Munich, Munich, 81377, Germany; Research Unit Radiation Cytogenetics, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany; Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer", Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany. Electronic address: unger@helmholtz-muenchen.de.

Keywords

External Resources

Popular Topics
Recent Journals